Breastfeeding Blog

The Business Intelligence firm La Merie S.L. reported that the HMG-CoA-reductase inhibitor atorvastatin remained the no.1 best selling blockbuster drug in 2006 with ww sales of US$ 13.6 bln for Pfizer and Astellas Pharma. Among the TOP 10 blockbuster drugs are four biologics (antibodies and proteins). A total of 114 distinct blockbuster drugs were identified with 2006 sales of more than US$ 1 bln each. Total revenues from sales of all blockbuster drugs in 2006 were US$ 233.7 bln of which 23.1 % were achieved by biologics. The best selling classes of blockbuster drugs were again HMG-Coa-reductase inhibitors of which AstraZeneca’s rosuvastatin showed the highest growth rate with 59 % over the previous year. Among the TOP 10 blockbuster drug classes were three biologics: erythropoietin, anti-TNF and insulin & insulin analogs. Blockbuster drugs were in the product portfolio of 30 biopharmaceutical companies. Pfizer was the leader in the TOP 10 class of blockbuster drug companies with sales of US$ 28.7 bln originating from nine blockbuster drugs. The TOP 10 companies had between four and 12 blockbuster drugs each to generate 2006 sales between US$ 9.4 bln and 28.7 bln per company. These results and more were found in a search conducted by La Merie Business Intelligence and published in a complimentary report on July 6, 2007. The document entitled “Blockbuster Drugs 2006″ can be acquired as a free download at La Merie’s News Center and Online Store PipelineReview (pipelinereview).

The “Blockbuster Drugs 2006″ report presents in tabular format 2006 sales figures of the 114 blockbuster drugs with sales of more than US$ 1 bln each by company and for a total of 30 companies. Further Tables summarize the TOP 10 list of companies with blockbuster drugs in 2006, the TOP 10 best selling blockbuster drug classes as an overview and the single blockbuster drugs by class. In addition, information is provided on brand and generic names, target, class of compound, originator and licensee companies, product category and major indications. All information is fully referenced by a hyperlink leading to the original source of information.

About La Merie

La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals.

lamerie.

About PipelineReview

PipelineReview is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. A free R&D Newletter conveniently brings via e-mail a daily selection of the most interesting news from biopharmaceutical R&D.

pipelinereview.

Now that politics has got in the way of commonsense and led to the demise of the planned joint Australia New Zealand Therapeutic Products Authority, the Government must explain what it is going to do to streamline the approval of pharmaceutical products in New Zealand, says the New Zealand Medical Association.

The proposed joint authority aimed to protect the health and safety of New Zealanders and Australians through the regulation of prescription and non-prescription medicines, complementary medicines, and medical devices.

The vast majority of the public lobbying over this legislation focussed solely on complementary medicines, but this in reality was only a small part of the proposal, said NZMA Chairman Dr Peter Foley.

New Zealand processes to regulate medicines are outdated and cannot cope with demand. For example, at present Medsafe takes 700 days to approve new medicines.

New Zealand does not currently require medical device or complementary medicine suppliers to show that their products are safe and effective before they can be sold. This is out of step with international best practice and means that action is only taken after problems are detected.

“The NZMA calls on the Government to tell the medical profession and others what it is going to do now to streamline the pharmaceutical approval system in New Zealand. And what approach will it be taking for the regulation of complementary medicines in New Zealand?” Dr Foley said.

nzma.nz

Pfizer on Thursday announced that the European Committee for Human Medicinal Products — an advisory panel of the European Medicines Agency — has recommended the sale and marketing of its antiretroviral drug maraviroc in the European Union, the AP/Houston Chronicle reports (AP/Houston Chronicle, 7/19).

Pfizer has proposed using the drug to treat people with advanced HIV or AIDS who have not responded to other medications. Maraviroc works by blocking a protein, called CCR5, on human immune system cells that HIV uses as a portal to enter and infect the cell. Pfizer plans to offer the drug with a test developed by Monogram Biosciences that determines if people are likely to respond to the treatment. Pfizer has proposed selling maraviroc under the brand name Celsentri. FDA last month issued an approval letter for maraviroc. An approvable letter means that FDA believes the drug is worth approving but needs additional information before doing so. The company is in discussions with the agency to address outstanding questions and finalize the product labeling as soon as possible (Kaiser Daily HIV/AIDS Report, 6/21). CHMP said it recommended approval of maraviroc for use with other antiretrovirals among adults. EMA will make its final decision in the coming months, Reuters reports (Reuters, 7/19).

“Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Interest in nasal sprays for systemic drug delivery has increased dramatically in the last five years, driven by the need to develop new alternatives to oral delivery for protein and peptide-based drugs, and the belief that intranasal drug delivery may lead to greater drug efficacy, speed of action, safety, and patient compliance. Systemic intranasal drug delivery leverages the patient-friendly and favorable pharmacodynamics and pharmacoeconomics of intranasal administration to deliver drugs systemically. Nasal delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs.

As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patient-friendly and cost-effective. Intranasal administration is well positioned to take advantage of these trends and evolve into a significant role in the future of pharmaceutical development and commercialization.

There are currently more than two-dozen companies actively pursuing intranasal drug delivery products. These companies believe the advantages of nasal drug delivery provide significant market opportunities, particularly against oral and injectable therapy. Systemic nasal sprays will grow at the expense of the predominant drug delivery methods which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.

Systemic Nasal Sprays: Markets & Opportunities, a recently released report, analyzes existing and emerging systemic nasal spray products, market participants, and key demand and technology factors influencing the commercial market and shaping growth in this sector. It is available from Greystone Associates by visiting

greystoneassociates/Intranasal.htm

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

greystoneassociates

The social stigma attached to urinary incontinence coupled with the side effects of some existing treatments are restraining market expansion. However, the recent launch of new and improved products, coupled with the anticipated launch of more novel offerings will help market participants to grow despite the challenges that exist in the market. Increasing awareness levels and priority given to urinary incontinence by both patients and medical professionals, will be key to widening the patient pool and boosting uptake levels.

New analysis from Frost & Sullivan European Urinary Incontinence Therapeutics Market, finds that the market was valued at $393.6 million in 2006 and estimates this to reach $967.0 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Urinary Incontinence Therapeutics Market, send an e-mail to Radhika Menon Theodore, Corporate Communications, at rmtheodorefrost with your full name, company name, title, telephone number, e-mail address, city, state and country. We will send you the information through e-mail upon receipt of the above information.

“The urinary incontinence therapeutics market in Europe will experience sustained growth in the coming years,” notes Frost & Sullivan Research Analyst Vaibhav Sarvesh, “Rising awareness allied with the expected launch of improved products will be the major drivers in market expansion.”

Current therapeutic options are primarily geared to treat urge urinary incontinence and have been associated with side effects that nullify are effecting the performance of the drugs. However, recently launched products have a better safety profile and have been well accepted. More products with novel approaches are set to be introduced in the market and boost revenue prospects.

However, the low importance given to the disease by physicians coupled with the limited awareness of this condition will pose significant challenges to market growth. Moreover, the SUI therapeutics market faces stiff competition from alternative treatment options, thereby restraining potential market development.

“Well-established drugs will face very stiff competition from more recently released therapeutics and will show continuous decline in their market share,” adds Mr. Sarvesh. “The expected launch of some novel therapies will further reduce the market share of the older drug therapies, but will benefit the market in general as it will induce more patients to embrace therapeutic treatment for their condition.”

Increasing importance given to urinary incontinence by physicians will be key in augmenting the number of patients adopting therapeutics options. Novel treatments, expected to be launched for the treatment of urinary incontinence, will also positively impact market growth.

“The lack of therapeutic options for SUI will present the most obvious lacunae in this market,” concludes Mr. Sarvesh. “Raising awareness levels about the sole therapeutic option available for SUI will be critical for its success.”

European Urinary Incontinence Therapeutics Market is part of the Pharmaceutical & Biotechnology Subscription, which also includes research in the following markets: European Endometriosis Therapeutics Market, European Blockbusters coming off patent – Opportunities for Generics, and European Osteoarthritis Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

frost.

Millennium Research Group (MRG) has conducted a detailed analysis of the neonatal and perinatal device market in its US Market Opportunities in Neonatal/Perinatal Monitoring 2007 report. The analysis reveals that a growing trend of women using assisted reproductive technologies such as in-vitro fertilization, combined with the increasing average age of mothers giving birth, will lead to more premature births.

Due to the growing rate of these premature births that will be characterized by low birth weight, more perinatal and neonatal devices will be needed in hospitals. Incubators, warmers, monitoring devices, and ventilators are being used more than ever to help newborns survive during the critical early stages of life.

“The large focus of resources towards neonatal care in hospitals combined with the large volume of births that occur in the US annually, will drive the markets for neonatal and perinatal devices,” says Ryan Goren, Analyst at MRG. “The health status of newborns is among the highest levels of priority in hospitals in the US and as a result, this will ensure that modern devices continue to be purchased in the future.”

US Market Opportunities in Neonatal/Perinatal Monitoring 2007 report includes coverage of industry competitors, including Atom Medical, Dräger Medical, Fisher & Paykel Healthcare, GE Healthcare, Huntleigh Healthcare, MAQUET, Philips Medical Systems, Puritan Bennett, Spacelabs Medical, and VIASYS Healthcare.

About Millennium Research Group

Millennium Research Group, a Decision Resources, Inc. company (DecisionResources), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

MRG

The recent recall of Roche’s antiretroviral drug Viracept worldwide has “disrupted treatment for tens of thousands of the world’s poorest patients, with no clear word from the manufacturer on when shipments will resume,” the New York Times reports (Rosenthal, New York Times, 7/23). The European Medicines Agency in June recalled Viracept because of contamination. Roche in a statement said that it is recalling all batches of the drug in cooperation with EMA and Swissmedic, Switzerland’s drug regulator, in Europe and other undisclosed countries. According to Roche, the drug was recalled after tests indicated that certain batches were contaminated with higher-than-normal levels of methane sulfonic acid ethyl ester — a chemical normally used in the drug in small quantities.

William Burns, CEO of Roche’s pharmaceutical division, said the impurity had been caused by the interaction of two chemicals in a vessel where the drug is produced. Investigators still are trying to determine what occurred in the Swiss plant where the drug is manufactured. It is believed that the contamination might have occurred in March and has affected supplies of the drug for three months. Roche later announced that it plans to establish patient registries to monitor the health of HIV-positive people who were taking the drug (Kaiser Daily HIV/AIDS Report, 6/25).

Although the recall “went largely unnoticed” in developing countries when it was announced, it has “caused growing concern among global health officials and in AIDS programs in many poor nations,” according to the Times. They say that Roche did an insufficient job of providing information to patients and officials about potential risks of Viracept and helping them to find affordable, alternative drugs, the Times reports. Roche said that it has been working with health officials worldwide and that risks associated with the affected Viracept batches are low. The company said it immediately notified health providers in affected countries to discontinue use of Viracept. Roche also said it would cover the “reasonable costs” of the recall but did not define “reasonable costs,” the Times reports.

Lembit Rago, an official with the World Health Organization, said that tens of thousands of people worldwide take Viracept, many of whom are impoverished and live in developing countries. The recall has “left those patients with the painful choice of discontinuing a lifesaving medicine or using a drug that might contain a dangerous contaminant,” according to the Times. WHO and EMA officials have said that Roche did not provide vital information for guarding public health, including where the affected drugs were shipped, the concentration of the contaminant and what the company plans to do for people taking the drug. EMA has canceled Roche’s license to manufacture Viracept, which also is known as nelfinavir.

Roche said that the recall affected “Europe and some other world regions” but has not been more specific, the Times reports. Although the company has been in talks with Pfizer about supplying Pfizer’s version of Viracept — which is made in the U.S., Canada and Japan — to some affected nations, regulatory and licensing issues could take “some time,” Roche spokesperson Martina Rupp said. Rupp said that Roche has shipped “at least one packet of Viracept with high levels of the impurity to 35 countries” but would not say which countries. Contaminants were “observed in batches of Viracept that had been released to countries since March 2007,” she added.

Rupp said that Roche made the worldwide recall to “avoid confusion,” adding that the company estimates about 45,000 people were affected by it. Roche is conducting studies on the issue, and the results will not be available for several months, according to Rupp.

In some countries, newer alternatives to Viracept are not available because they are not licensed or are too expensive, according to some people living with HIV and international health experts. In some countries, such as Panama, patients or treatment programs have made up the difference in cost between Viracept and more expensive alternatives. However, in countries like Venezuela, alternatives to the drug are unavailable.

Asia Russell, coordinator of international advocacy for Health Gap, said, “It seems that Roche has abandoned these patients since in many places there aren’t ready alternatives.” EMA spokesperson Martin Harvey-Allchurch said, “We have not gotten information, not even an order of magnitude.” Harvey-Allchurch added, “I understand sales figures are confidential, but I would have thought by now we would have this information” (New York Times, 7/23).

Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation. © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on VIRACEPT.

Shionogi & Co., Ltd. (Headquarters: Osaka, President: Motozo Shiono) announced that it will launch the non-pyrazolone antipyretic analgesic “Sedes ®V” with vitamin B1 on July 19, 2006.

In addition to its antipyretic and analgesic ingredients, Sedes ®V contains the vitamin B1 derivative dicethiamine hydrochloride, which aids pain relief by relaxing muscles through improved lactic acid metabolism. It exhibits an analgesic effect on headaches associated with stiffness of the neck and other forms of tension headache, and replaces vitamin B1 lost during chills and fever.

Through the addition of Sedes ®V as the fourth product in the Sedes® lineup, Shiongi aims to further develop the Sedes ® brand in the field of antipyretic analgesics in order to help individuals suffering from headaches, menstrual cramps, toothaches and other types of pain.

Product Overview

Active Ingredients (per tablet) Ethenzamide – 200mg Acetaminophen – 80mg Allylisopropylacetylurea – 30mg Anhydrous caffeine – 40mg Dicethiamine hydrochloride (vitamin B1 derivative) – 4mg

Indications

Headache, toothache, menstrual cramps, pain associated with stiffness of the neck, neuralgia, backache, pain from wounds, pain after tooth extraction, throat pain, earache, arthritis, muscle ache, pain associated with bruising, pain associated with fractures, pain associated with sprains, chills, fever

Directions / Dosage

Sedes ®V is best taken after meals in the quantities indicated below with cool or lukewarm water. Time between doses should be four or more hours.

Adults (over 15)
Single Dose -2 tablets
3 doses per 24 hour period maximum

Children (from 7 to 15 years)
Single Dose – 1 tablet
3 doses per 24 hour period maximum

Children under 7 – Do not take

Packaging, Quantity, Suggested Retail Price
10 tablets: 420 yen
30 tablets: 945 yen (includes tax)

###

shionogi.jp/index_e.html

Manhattan Research, a healthcare
market research services firm, today announced the leading pharmaceutical
product website destinations for physicians from its new physician research
study, “ePharma Physician(R) v7.0: The Future of Professional eMarketing.”

Top 10 Pharma Product Websites Among Physicians in 2007 Ranked by Number of U.S. Primary Care Physician Visitors

1. Januvia

2. Singulair

3. Advair

4. Chantix

5. Adderall XR

6. Byetta

7. Gardasil

8. Vytorin

9. Avandia

10. Concerta

“The latest research reveals physician site traffic is spread among
product sites of new and early launch stage treatments, those with clinical
news coverage, and consistent with years past, products with a significant
consumer advertising component,” states Mark Bard, president of Manhattan
Research. He continues, “We have seen these product sites evolve into brand
gateways with visitation from physicians, healthcare professionals, and
consumers and with the majority of the top 10 product sites changing from
year to year, there is clearly a need among physicians for the most
up-to-date product information.”

For the sixth consecutive year, Manhattan Research has determined the
leading online physician destinations based on the number of physician
visitors as well as the content satisfaction of those who visit. In-depth
analysis of top product and corporate pharmaceutical websites, health
portals, online journal sites, specialty-specific sites, newsletters and
society sites is now available as part of the ePharma Physician(R) v7.0
advisory service.

ePharma Physician(R) v7.0 reveals the relevant market share and
physician satisfaction for 300+ leading pharmaceutical product websites. A
complete list of available product sites is available at
manhattanresearch/ePP.aspx

ePharma Physician(R) v7.0 also includes the following specialist
segments in the research: Allergy and Immunology, Cardiology
(Cardiovascular Surgery and Interventional Cardiology), Dermatology,
Emergency Medicine, Endocrinology, Family Medicine/General Practice,
Gastroenterology, Infectious Disease or HIV physician, Internal Medicine,
Nephrology, Neurology, OB/GYN, Oncology-Hematology & Hematology,
Ophthalmology, Pediatrics, Psychiatry, Pulmonology, Radiology,
Rheumatology, Surgery (General and Orthopedic), and Urology.

Key Research Topics Covered

The ePharma Physician(R) v7.0 research reveals insight into the following:

– Electronic Detailing and Technology-Assisted Detailing

– Top Online Resources and CME

– Web 2.0 Technologies

– Technology at the Point of Care

– Pharmaceutical Customer Service Portals

– Top Product and Corporate Websites

Manhattan Research

In addition to ePharma Physician(R), Manhattan Research conducts
numerous research studies among physicians and consumers in the United
States and in Europe. Each study serves a unique purpose and focuses on
different aspects of information technology adoption. Broad research is
complemented by targeted analysis among more than 50 consumer therapeutic
segments and 25 physician specialist segments.

Manhattan Research
manhattanresearch

View drug information on Adderall XR.

New data from two new studies of Viramune® (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking VIRAMUNE (nevirapine) achieved a comparable virologic and immunologic response to patients taking efavirenz. The second study, NILE, examined the mechanism by which VIRAMUNE increases the level of high-density lipoprotein cholesterol (HDLc, also called “good cholesterol” because of its cardioprotective character) and confirmed again that VIRAMUNE increases HDL-cholesterol through 24 weeks.

“These studies show how to further maximise the benefits of treatment with VIRAMUNE. The findings of the NILE study are particularly encouraging as it was thought that some therapies for HIV may increase cardiovascular risk. What NILE has shown is that VIRAMUNE may increase good cholesterol in a manner which might be expected to reduce cardiovascular risk, and therefore, the study may help us identify promising novel targets for increasing good cholesterol,” Peter Reiss, Professor of Medicine, Academic Medical Centre, Amsterdam, Netherlands.

NILE (Nevirapine Intensive Lipid Evaluation)

The NILE study examined the way that VIRAMUNE increases HDL-cholesterol in 13 HIV positive patients with viral loads of

A retrospective intent-to-treat (ITT) analysis of the study examined 567 patients randomly assigned to receive VIRAMUNE 400 mg once daily (n=120), VIRAMUNE 200 mg twice daily (n=224) or efavirenz 600 mg once daily (n=223), and a nucleoside background containing stavudine and lamivudine, from 49 to 144 weeks of therapy. The primary endpoint was the percentage of treatment failures between week 49 and 144, defined as the occurrence of CDC-B/C events*, virologic failure, or a change in allocated NNRTI. Secondary endpoints included the percentage of patients with virologic failure, change in CD4 cell count, incidence of CDC-B/C events, and incidence of laboratory grade 3/4 adverse events.

Among patients included in the ITT analysis, the following was observed from week 49 to 144:

– There were no statistically significant differences with regard to the primary endpoint, treatment failure.
– Treatment response was comparable across all three study arms: 55% for VIRAMUNE once daily, 64% for VIRAMUNE twice daily, and 65% for efavirenz. Comparisons for all secondary analyses yielded no significant differences.
– The rates of virologic failure were similar for all three study arms: 4.9% for efavirenz, 5.8% for VIRAMUNE BID and 8.3% for VIRAMUNE QD.

The authors concluded:

– Change of medication was the most frequent reason for treatment failure;
– There was a low incidence of virologic failure during the 2nd and 3rd year;
– There was a continued increase in CD4+ T-cell counts;

About VIRAMUNE

VIRAMUNE is a product of original research done at Boehringer Ingelheim. VIRAMUNE was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs. VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on one principal clinical trial that demonstrated prolonged suppression of HIV-RNA and several smaller supportive studies. Studies have also shown that patients switching to VIRAMUNE from a PI-based regimen demonstrate an improved lipid profile while maintaining viral suppression. The most clinically important adverse events associated with VIRAMUNE are rash and hepatic events, which have included fatal cases. Any patient can experience hepatic events; however, female gender and higher CD4+ cell counts at initiation of therapy place patients at greater risk. Women with CD4+ cell counts >250 cells/mm3 are at the greatest risk. By application of the VIRAMUNE CD4+ guidelines the risk of hepatic events can be dramatically reduced. VIRAMUNE should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm3 or in adult males with CD4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk. The greatest risk of severe rash and hepatic events occurs in the first six weeks of therapy. It is essential that patients be monitored for these reactions at all times, and intensively during the first few months of therapy. VIRAMUNE should be discontinued and not restarted following severe hepatic, skin or hypersensitivity reactions.

Boehringer Ingelheim

Boehringer Ingelheim is committed to the research and development of novel antiretroviral agents. Apart from Viramune® (nevirapine), Aptivus® (tipranavir) is a new non-peptidic protease inhibitor, approved for combination antiretroviral treatment of HIV-1 infected adults that are highly pre-treated with virus resistant to multiple protease inhibitors. The company is committed to improving HIV therapy by providing physicians and patients with innovative antiretrovirals.

Boehringer Ingelheim is actively conducting clinical trial programs to further evaluate VIRAMUNE and APTIVUS for the treatment of HIV-1 infection. Boehringer Ingelheim recently announced the initiation of the ArTEN trial, which will compare the efficacy and safety of VIRAMUNE dosed once-or twice-daily versus atazanavir boosted with ritonavir in HIV-positive antiretroviral-naГЇve patients. The APTIVUS clinical trial program is comprised of ongoing and planned studies in more than 1,400 treatment-experienced patients, including the SPRING study, which is examining the benefits of APTIVUS in an ethnically and racially diverse highly treatment-experienced patient population and the POTENT study, which will compare the efficacy and safety of APTIVUS versus darunavir.

boehringer-ingelheim/hiv

Reference:

- Wit, F. et al. Three-year extended follow-up of the 2NN study: a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine, efavirenz or both drugs combined, together with stavudine and lamivudine. 4th International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; Sydney, Australia. Abstract #WEPEB032

- Sankatsing, R. et al. Nevirapine increases High Density Lipoprotein-cholesterol by stimulation of apolipoprotein AI synthesis. 4th International AIDS Society (IAS) conference on HIV Pathogenesis and Treatment; Sydney, Australia. Abstract #WEPEB120LB

*The U.S. Centers for Disease Control and Prevention (CDC) disease staging system assesses the severity of HIV disease by CD4 cell counts and by the presence of specific HIV-related conditions. Category B events are symptomatic conditions of HIV infection in adolescents or adults. Category C events are AIDS-indicator conditions, such as recurrent bacterial pneumonia, coccidioidomycosis and histoplasmosis. (Source: AIDS Education and Training Centers (AETC) National Resource Center)

View drug information on Aptivus; Viramune.